北海道におけるスモンの疫学的研究-2-スモンの性及び年令素因の検討

概要

論文の詳細を見る
Age and sex factors in SMON (subacute myelo-optic neuropathy) were studied from the records of 7, 425 in- and out- patients with various diseases including SMON, who received clioquinol at three hospitals in different localities of Hokkaido from January 1964 to September 1970.1) The morbidity rate of SMON in patients receiving 0.6-2.7g per day of clioquinol was found to increase with age. In the same age groups, the rate in females was always higher than in males, and the sex difference became larger with age.2) In two age groups, 10-39 and 40-59 years, in both sexes the average incidence of SMON rose gradually in parallel with the total amount of clioquinol administered. In those over 60 years of age, the rates increased rapidly and reached the highest levels at 40g and 80g in males and females, respectively.3) When the morbidity rate of SMON was plotted against the total dose of clioquinol administered [(g)/body weight (kg)] in three different age groups, the curve of the morbidity rate was higher with increasing total dose/body weight in the group below 40 years of age in men, while curves with two peaks, at 0.6-1.0g/kg and 2.2g/kg, were seen in men over 40 years of age. In women, in contrast, the curves had a single peak, irrespective of age.Further, the curves of males and females below 40 years of age and above 60 years of age were very simular in the dose range of 0.1-0.6g/kg.
日本衛生学会の論文